The effective dose of DIM reversed the upregulation of the expression of CCL-2, IL-6, and IL-8 in GC-MSCs by β-TrCP-mediated iκBα degradation and NFκB signaling pathway activation, thereby enhancing tumor progression (Figure 6). The gene discussed is NFKB1; the disease is neoplasm.